|[March 06, 2013]
Research and Markets: PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv)
has announced the addition of GlobalData's new report "PharmaPoint: HIV
- Germany Drug Forecast and Market Analysis to 2022" to their offering.
GlobalData has released its new Country report, PharmaPoint: HIV -
Germany Drug Forecast and Market Analysis to 2022. Human
Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed
millions of lives since its emergence. However, the advent of
antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a
deadly disease to a manageable chronic condition for most infected
individuals. Antiretroviral treatment not only reduces the viral load
and reconstitutes immune function, but also decreases infection
incidence rtes by limiting viral transmission.
The treatment algorithm in HIV has characteristically involved multiple
drug regimens designed to tackle the virus on different levels. In the
recent past, simplified dosing regimens through the emergence of single
tablet regimens (STRs) or fixed dose combination (FDC) therapies have
become increasingly popular amongst physicians and patients alike by
increasing clinical efficacy thresholds and enabling patient compliance.
Newer STRs are expected to be released and will replace Atripla as the
market leader during the forecast period. As a whole, the market share
of the STRs will be affected by key patent expiries, such as those of
BMS' Sustiva, which is a key component of Atripla. Combined with
healthcare budget restrictions imposed by the general financial
situation in Europe, this might lead to a drastic drop in Atripla sales
and increase the barrier to entry for novel STRs.
- Overview of Germany including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on the key drugs in Germany including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Germany from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting Germany HIV market.
For more information visit http://www.researchandmarkets.com/research/v74dvx/pharmapoint_hiv
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]